State Street Corp Sells 46,217 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

State Street Corp trimmed its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 0.4% during the third quarter, HoldingsChannel.com reports. The fund owned 10,970,746 shares of the biopharmaceutical company’s stock after selling 46,217 shares during the quarter. State Street Corp’s holdings in Amicus Therapeutics were worth $117,168,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. OLD Second National Bank of Aurora acquired a new position in shares of Amicus Therapeutics in the 3rd quarter worth approximately $26,000. Hazlett Burt & Watson Inc. raised its position in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 1,569 shares during the last quarter. Blue Trust Inc. boosted its stake in Amicus Therapeutics by 1,705.4% in the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 2,831 shares in the last quarter. Arcadia Investment Management Corp MI bought a new stake in shares of Amicus Therapeutics during the third quarter worth $32,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Amicus Therapeutics during the third quarter worth $55,000.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $9.36 on Monday. The firm has a fifty day moving average of $10.52 and a two-hundred day moving average of $10.62. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The stock has a market capitalization of $2.80 billion, a price-to-earnings ratio of -27.53 and a beta of 0.60. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57.

Analysts Set New Price Targets

FOLD has been the topic of several research reports. Guggenheim upped their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Cantor Fitzgerald upped their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Jefferies Financial Group initiated coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price objective on the stock. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Amicus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $16.88.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $10,161,054.84. This trade represents a 0.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 30,401 shares of company stock valued at $339,363 over the last three months. Company insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.